ArticleFrontiers in neuroscience2026
Integration of imaging and clinical biomarkers for cerebral infarction diagnosis via NeuroFusionNet.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral infarction remains a leading cause of mortality and long-term disability worldwide, demanding rapid and accurate diagnostic strategies. However, current assessments primarily rely on imaging interpretation, often neglecting valuable clinical and laboratory information that could enhance diagnostic precision. Methods: We developed NeuroFusionNet, a multi-modal deep learning framework that integrates imaging features with clinical biomarkers for binary classification of cerebral infarction and healthy controls. The model combines a ResNet-based visual encoder with a multilayer perceptron branch for clinical indicators, achieving end-to-end feature fusion and joint optimization. Results: NeuroFusionNet achieved superior diagnostic performance with an accuracy of 0.9655, precision of 0.9584, recall of 0.9584, and F1-score of 0.9584, significantly outperforming baseline models including ResNet, MobileNet, and GhostNet. The integration of imaging and clinical biomarkers effectively enhanced model sensitivity and robustness, demonstrating strong potential for real-world clinical application. Conclusion: Our findings highlight the clinical value of integrating imaging and laboratory data for precision diagnosis of cerebral infarction. NeuroFusionNet provides a scalable and interpretable framework that may support early detection and personalized management of cerebrovascular diseases in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.